GEN Exclusives

More »
New Products

Related to CE Mark for Rapid Acute Kidney Injury Test

    • DNA Reference Standard
    • Horizon Discovery
    • The Quantitative Multiplex DNA reference standard is intended for researchers assessing multiple biomarkers in a single assay using platforms such as next-generation sequencing. It can enable researchers to quantify a range of detection thresholds
    • Immunoassay System
    • Singulex
    • The Erenna® immunoassay system now benefits from a new high-definition single-molecule counting technology with which users can quantify previously undetectable biomarkers with LLoQ to femtogram levels, even in healthy populations. The system
    • Kidney Toxicity Panels
    • Bio-Rad
    • Developed through a partnership with Myriad RBM, the Bio-Plex Pro RBM assays enable the detection of multiple biomarkers in a single sample, which may reveal damage within hours of kidney injury. This early detection can improve drug testing in bot
    • Assays for Stem Cell Protein Markers
    • EMD Millipore
    • The Milliplex® MAP human stem cell pluripotency magnetic bead kits enable the analysis of many different pluripotency biomarkers in a single measurement. The kits examine protein biomarkers that indicate the potency of stem cells, enabling plu
    • Protein Biomarker Immunoassays
    • Olink Bioscience
    • Proseek® Multiplex is a generation of multiplexed protein biomarker immunoassays based on the Proximity Extension Assay (PEA) platform. Proseek Multiplex allows biomarker researchers to quantify 92 proteins in one microliter sample against a p
  • Page 1 of 1 (5 items) 1 

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?